Skip to content
AnalystLens

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jan 10, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed January 10, 2025
Period End
January 8, 2025
Security
LH
In the record · 2016–202610-K1310-Q338-K382

LH filed 13 annual reports (10-K), 33 quarterly reports (10-Q) and 382 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Sep ’17Sep ’17
  2. Auditor change8-K · Nov ’20Nov ’20
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed January 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K dated January 10, 2025 under Item 7.01 (Regulation FD Disclosure) to announce that its Board of Directors declared a cash dividend of $0.72a per share of common stock.

The dividend is payable on March 12, 2025, to stockholders of record as of the close of business on February 27, 2025. The filing is a routine capital return announcement and contains no financial results, guidance, or operational updates. The full details are provided in the press release furnished as Exhibit 99.1, dated January 8, 2025, which is incorporated by reference.

That press release describes Labcorp as a global laboratory services company serving doctors, hospitals, pharmaceutical companies, researchers and patients, with more than 67,000 employees serving clients in approximately 100 countries. For investors, the key takeaway is the declared quarterly dividend of $0.72b per share and its record and payment dates. The filing does not address the company's financial performance or outlook.

02—Key points

Key Highlights

  1. Board of Directors declared a cash dividend of $0.72 per share of common stock, announced January 8, 2025.
  2. Dividend payable March 12, 2025.
  3. Stockholders of record as of the close of business on February 27, 2025, are eligible to receive the dividend.
  4. Disclosure made under Item 7.01 (Regulation FD Disclosure), with the press release furnished as Exhibit 99.1.
  5. Exhibit 99.1 describes Labcorp as serving clients in approximately 100 countries with more than 67,000 employees.
  6. Exhibit 99.1 states the company supported 84% of new drugs and therapeutic products approved by the FDA in 2023 and performed more than 600 million tests for patients.

03—Questions

Frequently Asked Questions

  1. What dividend did Labcorp declare?

    Labcorp's Board of Directors declared a cash dividend of $0.72 per share of common stock, as announced on January 8, 2025.

  2. When will the dividend be paid?

    The dividend is payable on March 12, 2025.

  3. Who is eligible to receive the dividend?

    Stockholders of record as of the close of business on February 27, 2025 are eligible to receive the dividend.

  4. Does this filing include financial results or guidance?

    No. The filing is limited to the dividend declaration under Item 7.01 and references a press release (Exhibit 99.1) that announces the dividend. It does not contain financial results or outlook information.

04—Continue

← View all 8-K filings